RECEIVED CENTRAL FAX CENTER

DEC 0 7 2005



Vertex Pharmaceuticals Incorporated
130 Waverly Street • Cambridge, MA 02139-4242
Tel. 617.444.6100 • Fax 617.444.6483
http://www.vrtx.com

FAX TRANSMISSION

| То | USPTO |
|---------------------|-------------------------------------|
| Examiner | Michael P. Barker |
| Fax Number | (571) 273-8300 |
| From | Michael C. Badia |
| Date | December 7, 2005 |
| Application No. | 10/749,121 |
| Attorney Docket No. | VPI/02-05 US |
| | Response to Restriction Requirement |
| Total Pages | 11 |

Message or Comment

If any problems occur with this fax transmittal, please call (617) 444-6467 immediately.

PECEIVED
CENTRAL FAX CENTER
DEC 0 7 2005

Attorney Docket No.: VPI/02-05 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

Michael P. Barker

Group No.

1626

Applicant(s)

Jeffrey O. Saunders et al.

Serial No.

10/749,121

Confirmation No.

3285

Filed

December 30, 2003

Title

SULFHYDANTOINS AS PHOSPHATE

ISOSTERES

Certificate of Facsimile Transmission Under 37 CFR §1.8

I hereby certify that this correspondence and any documents referred to as attached hereto is/are being facsimile transmitted to the United States Patent and Trademark Office on December 7, 2005.

Lisa M. Romano
Typed of Printed Name

Signature

December 7, 2005

Cambridge, Massachusetts

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Sir:

Transmitted herewith: [X] a Response to Restriction Requirement; [] a Petition for Extension of Time; [] a substitute Specification; [] a Declaration; [] a Supplemental Declaration; [] a Power of Attorney; [] an Associate Power of Attorney; [] formal drawings; [] Notice of Appeal; [] Appeal Brief; [] Petition for Revival; to be filed in the above-identified patent application.

Applicants: Jeffrey O. Saunders et al. Application No. 10/749,121

FEE FOR ADDITIONAL CLAIMS

- [X] A fee for additional claims is not required.
- [] A fee for additional claims is required.

The additional fee has been calculated as shown below:

| _ | CLAIMS REMAINING AFTER AMENDMENT | HIGHES NUMBE PREVIO PAID FO | R USLY | PRESENT EXTRA | RATE | | ADDITIONAL FEES |
|-----------------|---|--------------------------------------|-----------|------------------|-------|---|--------------------|
| - TOTAL | CLAIMS | | * = | х | \$ 50 | = | \$ 0 |
| INDEPI CLAIM | ENDENT S | - | ** = | x | \$200 | = | \$ 0 |
| FIRST I | PRESENTATION O | F A CLAIM | | + | \$360 | = | \$ |
| * | If less than 20, insert | 20. | | TOTAL | | | <u>\$0</u> |

- ** If less than 3, insert 3.
 - [] A check in the amount of \$__ in payment of the filing fee is transmitted herewith.
 - Please charge \$___ to Deposit Account No. 50-0725 in payment of the filing fee. A duplicate copy of this transmittal letter is transmitted herewith.
 - [X] The Director is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

Applicants: Jeffrey O. Saunders et al. Application No. 10/749,121

EXTENSION FEE

- The following extension is applicable to the Response filed herewith; [] [] \$120.00 extension fee for response within first month pursuant to 37 C.F.R. § 1.136(a); [] \$450.00 extension fee for response within second month pursuant to 37 C.F.R. § 1.136(a); [] \$1,020.00 extension fee for response within third month pursuant to 37 C.F.R. § 1.136(a); [] \$1,590.00 extension fee for response within fourth month pursuant to 37 C.F.R. § 1.136(a); [] \$2,160.00 within fifth month pursuant to 37 C.F.R. § 1.136(a).
- A check in the amount of [] \$120.00; [] \$450.00; [] \$1,020.00; [] \$1,590.00; [] [] \$2,160.00 in payment of the extension fee is transmitted herewith.
- Please charge the extension fee in the amount of [] \$120.00; [] \$450.00; [] \$1,020.00; [] \$1,590.00; [] \$2,160.00 to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.
- The Director is hereby authorized to charge payment of any additional fees X required under 37 C.F.R. § 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

MISCELLANEOUS FEES

| [] | Please charge \$ to Deposit Account No. 50-0725 in payment of the for(37 C.F.R. \$). |
|-----|--|
| [X] | The Director is hereby authorized to charge payment of any additional fees required under 37 C.F.R. §, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith. |

Respectfully submitted,

Michael C. Badia, Reg. No. 51,424

Agent for Applicants

Vertex Pharmaceuticals Incorporated

130 Waverly Street

Cambridge, Massachusetts 02139

Tel: (617) 444-6467 Fax: (617) 444-6483 Customer No. 27916

RECEIVED CENTRAL FAX CENTER

DEC 0 7 2005

Attorney Docket No.: VPI/02-05 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

Michael P. Barker

Group No.

1626

Applicant(s)

Jeffrey O. Saunders et al.

Serial No.

10/749,121

Confirmation No.

3285

Filed

December 30, 2003

Title

SULFHYDANTOINS AS PHOSPHATE

ISOSTERES

Certificate of Facsimile Transmission Under 37 CFR §1.8

I hereby certify that this correspondence and any documents referred to as attached hereto is/are being facsimile transmitted to the United States Patent and Trademark Office on December 7, 2005.

Lisa M. Romano

Typed of Printed Name

December 7, 2005 Cambridge, Massachusetts

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Sir:

Transmitted herewith: [X] a Response to Restriction Requirement; [] a Petition for Extension of Time; [] a substitute Specification; [] a Declaration; [] a Supplemental Declaration; [] a Power of Attorney; [] an Associate Power of Attorney; [] formal drawings; [] Notice of Appeal; [] Appeal Brief; [] Petition for Revival; to be filed in the above-identified patent application.

Applicants: Jeffrey O. Saunders et al.

Application No. 10/749,121

FEE FOR ADDITIONAL CLAIMS

[X] A fee for additional claims is not required.

[] A fee for additional claims is required.

The additional fee has been calculated as shown below:

| - | CLAIMS REMAINING AFTER AMENDMENT | HIGHEST NUMBER PREVIOU PAID FOI | S USLY | PRESENT EXTRA | RATE | | ADDITIONAL FEES |
|---------------|---|--|-----------|------------------|-------|---|--------------------|
| - TOTAL | CLAIMS | • | * = | х | \$ 50 | = | \$ 0 |
| INDEP | ENDENT IS | - | ** = | х | \$200 | = | \$ 0 |
| FIRST MULT | PRESENTATION C IPLE DEPENDENT | OF A CLAIM | | + | \$360 | = | \$ |
| | If less than 20, inser | 1 20. | <u></u> | TOTAL | | | <u>\$0</u> |

- ** If less than 3, insert 3.
 - [] A check in the amount of \$__ in payment of the filing fee is transmitted herewith.
 - Please charge \$___ to Deposit Account No. 50-0725 in payment of the filing fee. A duplicate copy of this transmittal letter is transmitted herewith.
 - [X] The Director is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

Applicants: Jeffrey O. Saunders et al. Application No. 10/749,121

EXTENSION FEE

| [] | The following extension is applicable to the Response filed herewith; [] |
|----|--|
| ., | \$120.00 extension fee for response within first month pursuant to 37 C.F.R. § |
| | 1.136(a); [] \$450.00 extension fee for response within second month pursuant |
| | to 37 C.F.R. § 1.136(a); [] \$1,020.00 extension fee for response within third |
| | month pursuant to 37 C.F.R. § 1.136(a); [] \$1,590.00 extension fee for |
| | response within fourth month pursuant to 37 C.F.R. § 1.136(a); [] \$2,160.00 |
| | within fifth month pursuant to 37 C.F.R. § 1.136(a). |

- [] A check in the amount of [] \$120.00; [] \$450.00; [] \$1,020.00; [] \$1,590.00; [] \$2,160.00 in payment of the extension fee is transmitted herewith.
- Please charge the extension fee in the amount of [] \$120.00; [] \$450.00; [] \$1,020.00; [] \$1,590.00; [] \$2,160.00 to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.
- [X] The Director is hereby authorized to charge payment of any additional fees required under 37 C.F.R. § 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

MISCELLANEOUS FEES

| [] | Please charge \$ to Deposit Account No. 50-0725 in payment of the for(37 C.F.R. §). |
|-----|--|
| [X] | The Director is hereby authorized to charge payment of any additional fees required under 37 C.F.R. §, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith. |

Respectfully submitted,

Michael C. Badia, Reg. No. 51,424

Agent for Applicants

c/o Vertex Pharmaceuticals Incorporated

130 Waverly Street

Cambridge, Massachusetts 02139

Tel: (617) 444-6467 Fax: (617) 444-6483 Customer No. 27916

VPI/02-05 US

RECEIVED IN THE UNITED STATES PATENT AND TRADEMARK OFFICE CENTRAL FAX CENTER

DEC 0 7 2005

Examiner : Michael P. Barker

Group : 1626

Applicants : Jeffrey O. Saunders et al.

Serial No. : 10/749,121

Confirmation No. : 3285

Filed: December 30, 2003

For : SULFHYDANTOINS AS PHOSPHATE

ISOSTERES

Cambridge, Massachusetts December 7, 2005

Mail Stop Amendment Commissioner for Patents P.O.Box 1450 Alexandria, VA 22313-1450

RESPONSE TO OFFICE ACTION/RESTRICTION REQUIREMENT

Dear Sir:

This is in response to the November 15, 2005 Office Action setting forth an election/restriction requirement in the above-identified application. The time for reply to this Office Action is up to and including December 15, 2005. Therefore, submission of this response on December 7, 2005 is timely. Remarks begin at page 2.